Last reviewed · How we verify
NCT04604197: ANGELINE
ANGiographic Evaluation of Left Main Coronary Artery INtErvention
NA trial testing Angiography and Clinical Follow up in Coronary Occlusion in 400 participants. Participants enrolled and being followed up; not accepting new ones.
1 March 2026
Quick facts
| Lead sponsor | Fundación EPIC |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 400 |
| Start date | 16 April 2021 |
| Primary completion | 1 March 2026 |
| Estimated completion | 1 April 2026 |
| Sites | 30 locations across Spain |
Drugs / interventions tested
- Angiography and Clinical Follow up
- Clinical Follow up
Conditions studied
- Coronary Occlusion — all drugs for Coronary Occlusion →
- Left Main Coronary Artery Disease — all drugs for Left Main Coronary Artery Disease →
- Coronary Artery Stenosis — all drugs for Coronary Artery Stenosis →
- Coronary Disease — all drugs for Coronary Disease →
Sponsor
Fundación EPIC — full company profile →
Who can join
Adults 18 to 85, any sex, with Coronary Occlusion or Left Main Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess if an angiographic follow-up at 6 months after Percutaneous Coronary Intervention in Left Main Coronary Artery Disease decrease the composite objective of death, myocardial infarction, and stroke at 36 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04604197
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Occlusion
Currently open trials in the same condition.
- NCT06878729 — Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI · NA · recruiting
- NCT06528821 — AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS · active not recruiting
- NCT06542393 — PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG) · Phase 2 · recruiting
- NCT06681584 — Comparison of the Diagnostic Performance and Costs of FFRB Vs. Standard Care in Suspected Coronary Artery Disease. · active not recruiting
- NCT03588481 — IRIS- DESyne X2 in the IRIS-DES Registry · recruiting
Other Fundación EPIC trials
Trials by the same sponsor.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07260474 — Comparison of the Amplatzer Amulet Versus LAmbre Device for Left Atrial Appendage Closure · NA · not yet recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
- NCT07190690 — Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both · NA · recruiting
- NCT07256249 — Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selutio · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04604197 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundación EPIC
- Last refreshed: 13 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04604197.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing